solifenacin 5 mg

DRUG2 trials

Sponsors

Astellas Pharma Europe Ltd., Far Eastern Memorial Hospital

Conditions

Urinary Bladder DiseasesUrinary Bladder OveractiveUrinary Bladder, OveractiveUrologic Diseases

Phase 3

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

CompletedNCT01908829

Astellas Pharma Europe Ltd.Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases

Start: 2013-07-10End: 2014-11-25Updated: 2024-10-31

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Not yet recruitingNCT07114640

Far Eastern Memorial HospitalUrinary Bladder, Overactive

Start: 2025-08-07End: 2028-12-31Target: 220Updated: 2025-08-11

Related Papers

PD36-02 MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS: A RESPONDER ANALYSIS OF A RANDOMIZED, DOUBLE BLIND, PHASE 3B STUDY

The Journal of Urology2016-03-28

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

European Urology2016-03-08181 citations